Abstract:Objectives: A Patterns of Care Study (PCS) was performed in the largest regional medical center in Zhejiang Province, China. The hospital information system (HIS) was used to evaluate patient characteristics and changes in initial treatment patterns for prostate cancer and to determine recent predominant trends in treatment plans for prostate cancer (PCa) in China. Methods: Men who were newly diagnosed with localized or locally advanced PCa for 2010-2011 and 2016-2017 were identified in the HIS database. Patient characteristics and temporal trends in initial management were assessed, and differences between groups were evaluated for significance using Chi-square and Mann-Whitney U tests. Results: In total, 1792 patients met the study criteria, including 505 and 1287 patients in the 2010-2011 and 2016-2017 samples, respectively. The average age of patients diagnosed in the 2010-2011 PCS survey was 70 years, decreasing to 68 years when the 2016-2017 patients were included (P<0.001). In the 2010-2011 sample, 50.69% of the patients had an initial prostate-specific antigen (PSA) level ≥20 ng/ml. In contrast, the initial PSA level was 4-19.99 ng/ml for 66.67% of the patients in the 2016-2017 sample (P<0.001). Based on National Comprehensive Cancer Network (NCCN) criteria, the percentages of patients in low- and intermediate-risk groups increased from 33.06% to 54.78%; conversely, the percentages in high-risk, very high-risk, and regional (N1) groups decreased to a certain extent (P<0.001). According to European Association of Urology (EAU) criteria, the percentages of patients in low- and intermediate-risk groups increased from 32.07% to 53.69%, yet the percentage in the high-risk group decreased (P<0.001). The use of radical prostatectomy (RP) and radiation therapy (RT) increased from 48.32% to 76.46% and 5.35% to 16.94%, particularly in high-risk and low-risk groups, respectively, whereas the rates of hormone therapy (HT) and active surveillance and observation (AS&O) decreased from 32.28% to 4.27% and from 16.04% to 2.33%, respectively (P<0.001). A similar pattern was observed when patients were stratified by EAU risk group. Conclusions: The results of this real-world study in the largest regional medical center in Zhejiang Province, China, indicate that the predominant characteristics of PCa patients and trends in initial management are changing rapidly. We found the following: (a) a trend toward a decreased age among newly diagnosed patients; (b) a trend toward lower initial PSA levels; (c) a downward trend in risk group classification; (d) a significant increase in the likelihood of receiving RP, particularly in the high-risk group; (e) an increase in the rate of RP, mostly due to use of the Da Vinci robotic system; (f) a significant increase in the likelihood of receiving RT, especially in the low-risk group; and (g) a decrease in HT and AS&O.

Recent progress in early detection of prostate cancer

Development and Application of Prostate Cancer Gene 3 in Prostate Cancer

The Progress of Biomarkers in Prostate Cancer

Quantitative Detection of PCA3 mRNA and T1E4 mRNA-the Isoform of Fusion Gene TMPRSS2:ERG in Urine of Patients for the Early Clinical Diagnosis of Prostate Cancer

Applied Research of Prostate Specific Antigen Combined with Prostate Cancer Gene 3 in Diagnosis of Prostate Disease

Recent Advances in Imaging-Guided Interventions for Prostate Cancers.

Early Diagnosis of Prostate Cancer from the Perspective of Chinese Physicians.

China Guideline for the Screening and Early Detection of Prostate Cancer (2022, Beijing)

Prostate Cancer in Asia: A Collaborative Report

Progress in nuclear molecular probes for noninvasive prostate cancer clinical imaging

Advances in Biomarkers for the Early Diagnosis of Prostate Cancer.

Recent advances in nanomaterials for prostate cancer detection and diagnosis

Current status of prostate biopsy in Chinese Prostate Cancer Consortium member hospitals

CACA guidelines for holistic integrative management of prostate cancer

Recent progress in microRNA research for prostate cancer

Trends in Treatment for Prostate Cancer in China: Preliminary Patterns of Care Study in a Single Institution

Comparison of the clinicopathologic features of prostate cancer in US and Chinese populations

Biomarkers for Prostate Cancer: From Diagnosis to Treatment

PCA3 and TMPRSS2-ERG gene fusions as diagnostic biomarkers for prostate cancer

Function of PCA3 in Prostate Tissue and Clinical Research Progress on Developing a PCA3 Score.

Advances In Analytical Methodology Of Prostate Cancer Markers